The Special Commission of Inquiry into Healthcare Funding, led by The Honourable Justice Richard Beasley, conducted a major review of the NSW public healthcare system and how it is funded.
The Report is now available. (Link to Report). 41
Abuse: Stay of proceedings application & determination of the claim.
Davey v Want [2025] NSWDC 205 (Link to JADE).
Plaintiff claimed damages from the Defendant as a result of alleged misconduct (sexual assault) by the Defendant in 1971 and 1972 when the Plaintiff was 6 or 7 years old
PA Nursing Home Companies to Pay $15 Million for Healthcare Fraud
Two Pennsylvania nursing home operators were recently sentenced in federal court to pay more than $15 million in restitution in a healthcare fraud case. Comprehensive Healthcare Management Services, the operator of Brighton Rehabilitation and Wellness Center, and the affiliated operator
Council of the European Union backs reforms to the EU Regulatory Framework for Medicinal Products
Introduction
On 4 June, EU Member States, meeting in the Council of the European Union (‘Council’), have agreed on a position on the pharmaceutical reform package.
This agreement was reached despite significant divergences between EU Member States in the preceding
Abuse: Foster care & argued liability of the State – section 43A CLA NSW.
MTH v State of New South Wales [2025] NSWCA 122 (Link to Caselaw).
This somewhat complex appeal related to claims against the State of New South Wales and against two foster carers, Mr & Mrs Croft. Mr Croft was
Advisory: AION Vision Side Effect: Ozempic, Wegovy, Rybelsus
The Eye Condition AION Diagnosis Can Include NAION Due to Semaglutide Use
(Posted by Tom Lamb at Drug Injury Watch)
This article discusses a lesser-known possible vision side effect for Ozempic, Wegovy, and Rybelsus, diagnosed as anterior
The European Medicines Agency Proposes Streamlined Pathway for the Approval of Biosimilar Medicinal Products in the EU
The European Medicines Agency (EMA) has published a draft Reflection Paper proposing a streamlined pathway for the approval for certain biosimilar medicinal products (biosimilars) in the EU by reducing the clinical data requirements where justified.
Biosimilars are biological medicinal products
Federal District Court Upholds Authority of HHS to Pre-Approve 340B Rebate Programs; HRSA Submits Proposed 340B Rebate Guidance
A federal judge in D.C. recently ruled in favor of the U.S. Health Resources and Services Administration (“HRSA”), an administrative agency under the U.S. Department of Health and Human Services (“HHS”), by finding that drug manufacturers must obtain pre-approval from
Healthcare & Life Sciences Private Equity Deal Tracker: Edgewater Invests in CBCC Global Research
NDIS: Whether responsible for supports after work injury.
Santagada and CEO, National Disability Insurance Agency (Practice and procedure) [2025] ARTA 676 (Link to JADE).
This decision appears to be the first to address the question of whether the NDIS (following legislative amendments in 2024) is responsible for